CL2008001626A1 - Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. - Google Patents
Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.Info
- Publication number
- CL2008001626A1 CL2008001626A1 CL2008001626A CL2008001626A CL2008001626A1 CL 2008001626 A1 CL2008001626 A1 CL 2008001626A1 CL 2008001626 A CL2008001626 A CL 2008001626A CL 2008001626 A CL2008001626 A CL 2008001626A CL 2008001626 A1 CL2008001626 A1 CL 2008001626A1
- Authority
- CL
- Chile
- Prior art keywords
- prophylaxis
- cancer
- treatment
- pharmaceutical agent
- compounds derived
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
Compuestos derivados de heterociclos fusionados, agente farmacéutico que los comprende y su uso en la profilaxis y tratamiento del cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007149781 | 2007-06-05 | ||
JP2007223284 | 2007-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008001626A1 true CL2008001626A1 (es) | 2009-06-05 |
Family
ID=39684216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008001626A CL2008001626A1 (es) | 2007-06-05 | 2008-06-04 | Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. |
Country Status (9)
Country | Link |
---|---|
US (1) | US8304557B2 (es) |
EP (1) | EP2162445B1 (es) |
JP (1) | JP5352476B2 (es) |
AR (1) | AR066845A1 (es) |
CA (1) | CA2689514C (es) |
CL (1) | CL2008001626A1 (es) |
PE (1) | PE20090370A1 (es) |
TW (1) | TW200904816A (es) |
WO (1) | WO2008150015A1 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2008001626A1 (es) | 2007-06-05 | 2009-06-05 | Takeda Pharmaceuticals Co | Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. |
US8324395B2 (en) | 2007-08-23 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
EP2184285B1 (en) * | 2007-08-29 | 2015-11-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
EP2444403A1 (en) * | 2008-04-18 | 2012-04-25 | Shionogi Co., Ltd. | Heterocyclic compound having inhibitory activity on PI3K |
US8445509B2 (en) | 2008-05-08 | 2013-05-21 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivatives and use thereof |
WO2010010186A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
JP5579619B2 (ja) * | 2008-12-01 | 2014-08-27 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
US8501936B2 (en) | 2009-06-05 | 2013-08-06 | Cephalon, Inc. | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives |
JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
US8754219B2 (en) * | 2010-04-27 | 2014-06-17 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
CA2798578C (en) | 2010-05-21 | 2015-12-29 | Chemilia Ab | Novel pyrimidine derivatives |
EP2423208A1 (en) * | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmaceutically active compounds as Axl inhibitors |
EP2688883B1 (en) | 2011-03-24 | 2016-05-18 | Noviga Research AB | Pyrimidine derivatives |
UY34305A (es) | 2011-09-01 | 2013-04-30 | Novartis Ag | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar |
US9023865B2 (en) * | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
WO2014052566A1 (en) * | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
US9233979B2 (en) | 2012-09-28 | 2016-01-12 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
GB201223308D0 (en) | 2012-12-21 | 2013-02-06 | Univ Sunderland | Enzyme inhibitors |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
MX2020001793A (es) * | 2017-08-17 | 2020-07-22 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. |
WO2020201773A1 (en) * | 2019-04-05 | 2020-10-08 | Storm Therapeutics Ltd | Mettl3 inhibitory compounds |
EP4146639A1 (en) | 2020-05-06 | 2023-03-15 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
WO2023009708A1 (en) * | 2021-07-29 | 2023-02-02 | Ajax Therapeutics, Inc. | Heteroaryloxy triazolo- and imidazo-azines as jak2 inhibitors |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2399026A (en) * | 1941-02-06 | 1946-04-23 | Chem Ind Basel | Amides of 2-aminoarylenethiazoles |
US4096264A (en) * | 1975-12-09 | 1978-06-20 | Merck & Co., Inc. | Certain substituted imidazo [1,2-a] pyridines |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
NZ503432A (en) | 1997-09-26 | 2002-11-26 | Zentaris Gmbh | Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function |
US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
WO2000042012A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
GB9900752D0 (en) * | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
DE60033857T2 (de) * | 1999-01-22 | 2007-10-25 | Kirin Beer K.K. | Derivate des N-((Chinolinyl)oxy)-phenyl)-Harnstoffs und des N-((Chinazolinyl)oxy)-phenyl)-Harnstoffs mit Antitumor Aktivität |
EP1193255A4 (en) | 1999-07-01 | 2002-08-07 | Ajinomoto Kk | HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS IN MEDICINE |
NZ518028A (en) | 1999-11-05 | 2004-03-26 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
JP2003521543A (ja) | 2000-02-07 | 2003-07-15 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 2−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用 |
ME00415B (me) | 2000-02-15 | 2011-10-10 | Pharmacia & Upjohn Co Llc | Pirol supstituisani 2-indol protein kinazni inhibitori |
WO2001066539A1 (en) | 2000-03-06 | 2001-09-13 | Smithkline Beecham P.L.C. | Imidazol derivatives as raf kinase inhibitors |
GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
CN1471523A (zh) | 2000-09-21 | 2004-01-28 | ʷ | 咪唑类棉子糖激酶抑制剂 |
DE60126997T2 (de) | 2000-10-20 | 2007-10-25 | Eisai R&D Management Co., Ltd. | Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen |
JP2004517080A (ja) * | 2000-11-29 | 2004-06-10 | グラクソ グループ リミテッド | Tie−2および/またはvegfr−2の阻害剤として有用なベンゾイミダゾール誘導体 |
GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
EP1423383B1 (en) | 2001-09-05 | 2008-08-06 | Smithkline Beecham Plc | Pyridine substituted furan derivatives as raf kinase inhibitors |
GB0121488D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
GB0121494D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
US20040192689A1 (en) | 2001-09-05 | 2004-09-30 | Dean David Kenneth | Heterocycle-carboxamide derivatives as raf kinase inhibitors |
US7338959B2 (en) | 2002-03-01 | 2008-03-04 | Smithkline Beecham Corporation | Diamino-pyrimidines and their use as angiogenesis inhibitors |
AU2003226211B2 (en) * | 2002-03-29 | 2008-05-29 | Novartis Vaccines And Diagnostics, Inc. | Substituted benzazoles and use thereof as RAF kinase inhibitors |
US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
US7531553B2 (en) * | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
US7893096B2 (en) | 2003-03-28 | 2011-02-22 | Novartis Vaccines And Diagnostics, Inc. | Use of small molecule compounds for immunopotentiation |
DE10334663A1 (de) | 2003-07-30 | 2005-03-10 | Merck Patent Gmbh | Harnstoffderivate |
CA2535347A1 (en) * | 2003-08-15 | 2005-03-03 | Merck & Co., Inc. | 4-cycloalkylaminopyrazolo pyrimidine nmda/nr2b antagonists |
DE10337942A1 (de) * | 2003-08-18 | 2005-03-17 | Merck Patent Gmbh | Aminobenzimidazolderivate |
DE602004021838D1 (de) | 2003-10-16 | 2009-08-13 | Novartis Vaccines & Diagnostic | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
WO2005112932A2 (en) | 2004-05-07 | 2005-12-01 | Exelixis, Inc. | Raf modulators and methods of use |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
KR20060079098A (ko) | 2004-12-31 | 2006-07-05 | 주식회사 엘지생명과학 | 신규한([1,3]티아졸로[5,4-b]피리딘-2-일)-2-카르복사마이드유도체 |
WO2006076376A1 (en) | 2005-01-11 | 2006-07-20 | Medicinova, Inc. | Topical treatment of solid tumors and ocular neovascularization |
WO2007007886A1 (en) * | 2005-07-11 | 2007-01-18 | Mitsubishi Tanabe Pharma Corporation | An oxime derivative and preparations thereof |
TWI387592B (zh) | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
BR122018075851B1 (pt) * | 2005-11-15 | 2022-01-11 | Array Biopharma Inc | Compostos relacionados ao tratamento de doença hiperproliferativa e processos para preparar compostos |
WO2007058482A1 (en) * | 2005-11-16 | 2007-05-24 | Lg Life Sciences, Ltd. | Novel inhibitors of protein kinase |
WO2007121484A2 (en) | 2006-04-19 | 2007-10-25 | Novartis Ag | 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling |
US8161530B2 (en) * | 2006-07-11 | 2012-04-17 | Identity Metrics, Inc. | Behaviormetrics application system for electronic transaction authorization |
JPWO2008016131A1 (ja) | 2006-08-04 | 2009-12-24 | 武田薬品工業株式会社 | 縮合複素環化合物 |
CL2007002261A1 (es) | 2006-08-04 | 2008-05-02 | Takeda Pharmaceutical | Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer. |
JP4328820B2 (ja) | 2007-01-10 | 2009-09-09 | 田辺三菱製薬株式会社 | 医薬組成物 |
WO2008084873A1 (ja) | 2007-01-10 | 2008-07-17 | Mitsubishi Tanabe Pharma Corporation | オキシム誘導体 |
CL2008001626A1 (es) | 2007-06-05 | 2009-06-05 | Takeda Pharmaceuticals Co | Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. |
US8324395B2 (en) | 2007-08-23 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
EP2184285B1 (en) | 2007-08-29 | 2015-11-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
WO2009028655A1 (ja) | 2007-08-30 | 2009-03-05 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
US8445509B2 (en) * | 2008-05-08 | 2013-05-21 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivatives and use thereof |
JO3101B1 (ar) * | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
-
2008
- 2008-06-04 CL CL2008001626A patent/CL2008001626A1/es unknown
- 2008-06-04 PE PE2008000947A patent/PE20090370A1/es not_active Application Discontinuation
- 2008-06-04 JP JP2009549311A patent/JP5352476B2/ja active Active
- 2008-06-04 WO PCT/JP2008/060629 patent/WO2008150015A1/en active Application Filing
- 2008-06-04 EP EP08765409.1A patent/EP2162445B1/en active Active
- 2008-06-04 US US12/133,063 patent/US8304557B2/en active Active
- 2008-06-04 AR ARP080102359A patent/AR066845A1/es unknown
- 2008-06-04 CA CA2689514A patent/CA2689514C/en not_active Expired - Fee Related
- 2008-06-04 TW TW097120686A patent/TW200904816A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2010527909A (ja) | 2010-08-19 |
EP2162445B1 (en) | 2013-11-27 |
TW200904816A (en) | 2009-02-01 |
CA2689514A1 (en) | 2008-12-11 |
CA2689514C (en) | 2015-09-29 |
JP5352476B2 (ja) | 2013-11-27 |
WO2008150015A1 (en) | 2008-12-11 |
AR066845A1 (es) | 2009-09-16 |
US20090163488A1 (en) | 2009-06-25 |
US8304557B2 (en) | 2012-11-06 |
EP2162445A1 (en) | 2010-03-17 |
PE20090370A1 (es) | 2009-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008001626A1 (es) | Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. | |
CL2008002097A1 (es) | Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2019000941A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
CL2012000772A1 (es) | Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata. | |
CL2011000454A1 (es) | Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
CL2016001604A1 (es) | “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct | |
CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
CL2008001540A1 (es) | Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2011000191A1 (es) | Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
CL2015003280A1 (es) | Derivados de benzimidazol como inhibidores de bromodominio | |
CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
UY30846A1 (es) | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos | |
CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
CL2007002167A1 (es) | Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer. | |
CL2008002397A1 (es) | Compuestos derivados de imidazoles biciclicos fusionados; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar neoplasia benigna o maligna. | |
CL2011001255A1 (es) | Combinaciones farmaceutica que comprende un anticuerpo que reconoce especificamente cd38 y al menos vincristina; y uso del anticuerpo que reconoce especificamente cd38 para el tratamiento del cancer. | |
ECSP10010548A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
CL2012001405A1 (es) | Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer. | |
CL2008001076A1 (es) | Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2011003350A1 (es) | Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
CL2009000483A1 (es) | Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer. | |
CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
CL2012002250A1 (es) | Compuestos heterociclicos fusionados derivados de pirimidinonas, inhibidores potentes de cdc7; composicion farmaceutica; y su uso en la prevencion o el tratamiento del cancer. |